The University of Southampton

Dr Juliet Gray MA, MB BS, MRCPCH, PhD

Senior Lecturer in Paediatric Oncology

Dr Juliet Gray's photo
Related links

Dr Juliet Gray is Senior Lecturer in Paediatric Oncology within Medicine at the University of Southampton.

Dr Gray graduated from Cambridge University and the Royal Free Hospital School of Medicine. She completed her clinical training in Paediatric Oncology at Southampton, Great Ormond Street and the Royal Marsden hospitals. During her training she was awarded a Cancer Research UK Clinical Research Fellowship, which allowed her to complete a PhD in cancer immunotherapy within the Cancer Sciences Unit, University of Southampton. In 2006, she was appointed at a Walport Clinical Lecturer in Paediatric Oncology, and as a Senior Lecturer in Paediatric Oncology in 2010. She is an honorary Consultant in Paediatric Oncology at University Hospital Southampton NHS Foundation Trust (UHSFT).

Dr Gray is a member of the NCRI Children’s Cancer and Leukaemia CSG Neuroblastoma Subgroup, the SIOP European Neuroblastoma Research Network and the UK Children’s Cancer and Leukaemia Group (CCLG) New Agents Group. She is the CCLG Clinical Trial Lead for the Southampton Paediatric Oncology Principal Treatment Centre, Chair of the Southampton Paediatric Chemotherapy Group and a member of UHSFT Drugs Committee.


MA, Medical Sciences Tripos, Cambridge University (1991)
MB BS, University of London (1994)
PhD, Cancer Immunotherapy, University of Southampton (2007)

Appointments held

SHO in Paediatric Oncology, Great Ormond Street Hospital (1998)

Paediatric Oncology Clinical Research Fellow, Royal Marsden Hospital (1999)

General Paediatric Registrar, Portsmouth Hospitals (1999-2001)

Paediatric Oncology Registrar, Southampton General Hospital (2001-2002)

Cancer Research UK Clinical Research Fellow, Cancer Sciences Division, University of Southampton (2002-2006)

Bone Marrow Transplant Fellow, Royal Marsden Hospital (2007-2008)

Clinical Lecturer in Paediatric Oncology, University of Southampton (2006-2010)

Senior Lecturer in Paediatric Oncology, University of Southampton (2010 - present)





Research interests

Dr Gray’s main research interest is in the development of new immunotherapies to treat neuroblastoma, one of the commonest childhood cancers. Neuroblastoma is a tumour of neuroectodermal origin that usually develops in very young children. Unfortunately in the majority of children the disease is metastatic by the time of diagnosis, and survival rates for these children remain poor despite intensive conventional therapies. Toxicity from these therapies is significant and new therapies are needed to improve outcome. Immunotherapy is an attractive therapeutic option for these children because it potentially offers a highly specific way of targeting neuroblastoma cells and sparing normal tissues. Evidence of spontaneous anti-neuroblastoma immune responses is found in most children with the disease, but in general these endogenous responses are weak and fail to control disease. Monoclonal antibodies targeting the GD2 antigen have already shown clinical benefit in children with neuroblastoma, and one focus of Dr Gray’s work is aimed at understanding how these antibodies work, in order to optimise and improve their therapeutic effect. The other major focus of Dr Gray’s work is on using immunomodulatory monoclonal antibodies to generate therapeutic anti-neuroblastoma immunity. She has found that several of these agents (anti-4-1BB, anti-CTLA-4 and anti-CD40) show very promising effects in pre-clinical neuroblastoma models, with eradication of established disease and long-term survival. In more aggressive models, although these antibodies are not effective as single agent, combining them with peptide vaccination provides successful long-term therapy. Current work is establishing which combination of these antibodies and peptide vaccines is most potent, and it is anticipated that this will be taken forward to Phase I trial in children in the near future.

Finally, Dr Gray’s is investigating the immune response to vaccination in children who are receiving chemotherapy. She is Chief Investigator of a multi-centre study investigating whether pneumococcal conjugate vaccines can be used to generate effective anti-pneumococcal immunity in children receiving chemotherapy for Acute Lymphoblastic Leukaemia. The centre will recruit 120 children from 7 paediatric oncology centres and is funded by a NIHR Research for Patient Benefit grant.

Academic unit(s)

Cancer Sciences Academic Unit

Affiliate academic unit(s)

Cancer Sciences Research group

Postgraduate student supervision


Carol Wareham


Dr Juliet Gray
Phone: (023) 8120 6639 Fax: (023) 8120 4061 Email:

Room Number:SGH/Tenovus/MP88

Share this profile Facebook Google+ Twitter Weibo

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.